Cardiovascular considerations in treatment
| Cardiovascular concerns | Treatment considerations |
| STEMI and NSTEMI | Primary PCI vs thrombolytics |
| Myocardial injury | Worse prognosis, monitoring rising trends |
| Hypercoaulable state | Thromboprophylaxis |
| ACEI or ARB use | Continue treatment currently, await further studies |
| HCQ, CQ and/or azithromycin use | QTc monitoring, avoid other QTc prolonging drugs |
| Immunosupression/Immunomodulation | Maybe helpful in selected patients with cytokine storm |
| MCS | IABP and VA ECMO might be used for support in cardiogenic shock |
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; CQ, chloroquine; HCQ, hydroxychloroquine; IABP, intra-aortic balloon pump; MCS, mechanical circulatory support; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutanous coronary intervention; STEMI, ST-elevation myocardial infarction; VA ECMO, venoarterial extracorporeal membrane oxygenation.